Completed PHASE2 INTERVENTIONAL 1-arm NCT00374140

Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer

Sponsor: Ahmad Tarhini

Updated 8 times since 2017 Last updated: Sep 18, 2017 Started: Oct 31, 2006 Primary completion: Dec 31, 2008 Completion: Jun 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Small Cell Lung Cancer, this trial is completed. The trial is conducted by Ahmad Tarhini and has accumulated 8 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Nov 2017 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Nov 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Oct 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ahmad Tarhini
Novartis Pharmaceuticals

Data source: University of Pittsburgh

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beaver, United States , Clairton, United States , Greensburg, United States , Indiana, United States , Johnstown, United States , McKeesport, United States , Monroeville, United States , Moon Township, United States , New Castle, United States , Pittsburgh, United States and 4 more locations